Recently, ADAR1 was identified as a critical factor contributing to drug resistance in cancer cells, and the aberrant expression of ADAR1 promotes resistance to BET inhibitors in pancreatic cancer [377,378,379] (Table 2). Here, ADAR is linked to familial pancreatic carcinoma.